Please assess the completion status of the following clinical trial:

Trial Title: Identifying the Optimal Neural Target for Misophonia Interventions

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Interested participants will be excluded if:~1. current or past history of mania or psychosis,~2. verbal IQ \< 70,~3. not medically cleared for TMS or fMRI (for example taking medications known to reduce the seizure threshold such as Lamictal, Lithium, Clozaril, stimulants including the ADHD medications (e.g. Ritalin, Adderall), Wellbutrin/Buproprion, Provigil (Modafinil), Aminophylline, and Theophylline, implants, TBI, stroke, etc),~4. going to jail in the next 2 months,~5. pregnant,~6. high risk for suicide~7. moderate/severe current alcohol or substance dependence,~8. cannot come to Duke for the three study visits.~Inclusion criteria are:~1. stable psychotherapy and medication for at least 4 weeks~2. self reports high emotional dysregulation OR misophonia~Participants will be matched on gender and age between the two groups

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Misophonia Group (Type: EXPERIMENTAL): Participants who endorse Misophonia will undergo a neuroimaging session to identify different neurostimulation targets. Then Misophonic participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
- Emotional Dysregulation Clinical Group (Type: ACTIVE_COMPARATOR): Participants who self report high emotional dysregulation and who meet diagnostic criteria for a DSM disorder will undergo a neuroimaging session to identify different neurostimulation targets. Then these participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.

Based on this trial design, predict the completion outcome and termination type (if applicable).